GW Pharmaceuticals Plc (GWP) - Financial and Strategic SWOT Analysis Review

  • ID: 1292025
  • SWOT Analysis
  • 50 pages
  • GlobalData
  • GW Pharmaceuticals plc
1 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Biogen Inc
  • Echo Pharmaceuticals BV
  • Evotec AG
  • Immupharma Plc
  • Insys Therapeutics Inc
  • MORE
GW Pharmaceuticals Plc (GWP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing products for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy syndrome, glioma, schizophrenia, autism among others. The company has subsidiaries in Australia, the US, England and Wales, and Guernsey. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc Key Recent Developments

May 08, 2018: GW Pharmaceuticals Announces Fiscal Second Quarter 2018 Financial Results
Feb 05, 2018: GW Pharmaceuticals Reports Q1 Fiscal 2018 Financial Results
Dec 21, 2017: GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors
Dec 04, 2017: GW Pharmaceuticals Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress
Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca Plc
  • Biogen Inc
  • Echo Pharmaceuticals BV
  • Evotec AG
  • Immupharma Plc
  • Insys Therapeutics Inc
  • MORE
Section 1 - About the Company
  • GW Pharmaceuticals Plc - Key Facts
  • GW Pharmaceuticals Plc - Key Employees
  • GW Pharmaceuticals Plc - Key Employee Biographies
  • GW Pharmaceuticals Plc - Major Products and Services
  • GW Pharmaceuticals Plc - History
  • GW Pharmaceuticals Plc - Company Statement
  • GW Pharmaceuticals Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • GW Pharmaceuticals Plc - Business Description
  • Business Segment: Commercial
  • Overview
  • Performance
  • Business Segment: Pipeline R&D
  • Overview
  • Performance
  • Business Segment: Sativex R&D
  • Overview
  • Performance
  • Geographical Segment: Asia/Other
  • Performance
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: Europe (Excluding the UK)
  • Performance
  • Geographical Segment: The UK
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • GW Pharmaceuticals Plc - Corporate Strategy
  • GW Pharmaceuticals Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • GW Pharmaceuticals Plc - Strengths
  • GW Pharmaceuticals Plc - Weaknesses
  • GW Pharmaceuticals Plc - Opportunities
  • GW Pharmaceuticals Plc - Threats
  • GW Pharmaceuticals Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • GW Pharmaceuticals Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Dec 21, 2017: GW Pharmaceuticals Announces the Appointment of Three New Independent Members to its Board of Directors
  • Dec 04, 2017: GW Pharmaceuticals Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress
  • Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results
  • May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments
  • May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress
  • Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director - UK
  • Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals
  • Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • GW Pharmaceuticals Plc, Key Facts
  • GW Pharmaceuticals Plc, Key Employees
  • GW Pharmaceuticals Plc, Key Employee Biographies
  • GW Pharmaceuticals Plc, Major Products and Services
  • GW Pharmaceuticals Plc, History
  • GW Pharmaceuticals Plc, Other Locations
  • GW Pharmaceuticals Plc, Subsidiaries
  • GW Pharmaceuticals Plc, Key Competitors
  • GW Pharmaceuticals Plc, Ratios based on current share price
  • GW Pharmaceuticals Plc, Annual Ratios
  • GW Pharmaceuticals Plc, Annual Ratios
  • GW Pharmaceuticals Plc, Annual Ratios
  • GW Pharmaceuticals Plc, Interim Ratios
  • GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • GW Pharmaceuticals Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • GW Pharmaceuticals Plc, Performance Chart (2013 - 2017)
  • GW Pharmaceuticals Plc, Ratio Charts
  • GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • GW Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Zynerba Pharmaceuticals Inc
  • Zogenix Inc
  • Sinclair Pharma Plc
  • Oxford BioMedica Plc
  • Napp Pharmaceuticals Ltd
  • Insys Therapeutics Inc
  • Immupharma Plc
  • Evotec AG
  • Echo Pharmaceuticals BV
  • Contango Asset Management Ltd
  • Biogen Inc
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll